LT2948559T - Kv1.3 antagonistai ir jų panaudojimo būdai - Google Patents

Kv1.3 antagonistai ir jų panaudojimo būdai

Info

Publication number
LT2948559T
LT2948559T LTEP14743871.7T LT14743871T LT2948559T LT 2948559 T LT2948559 T LT 2948559T LT 14743871 T LT14743871 T LT 14743871T LT 2948559 T LT2948559 T LT 2948559T
Authority
LT
Lithuania
Prior art keywords
antagonists
Prior art date
Application number
LTEP14743871.7T
Other languages
English (en)
Inventor
Ellen Chi
Wilson EDWARDS
Chichi Huang
Wai-Ping Leung
Ronald Swanson
Alan Wickenden
Original Assignee
Janssen Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech, Inc. filed Critical Janssen Biotech, Inc.
Publication of LT2948559T publication Critical patent/LT2948559T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Insects & Arthropods (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
LTEP14743871.7T 2013-01-25 2014-01-24 Kv1.3 antagonistai ir jų panaudojimo būdai LT2948559T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361756777P 2013-01-25 2013-01-25
US201361757389P 2013-01-28 2013-01-28
PCT/US2014/012932 WO2014116937A1 (en) 2013-01-25 2014-01-24 Kv1.3 antagonists and methods of use

Publications (1)

Publication Number Publication Date
LT2948559T true LT2948559T (lt) 2018-06-25

Family

ID=51228060

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14743871.7T LT2948559T (lt) 2013-01-25 2014-01-24 Kv1.3 antagonistai ir jų panaudojimo būdai

Country Status (29)

Country Link
US (2) US10179808B2 (lt)
EP (1) EP2948559B1 (lt)
JP (1) JP6469590B2 (lt)
KR (1) KR102268830B1 (lt)
CN (1) CN104937105A (lt)
AU (1) AU2014209227B2 (lt)
BR (1) BR112015017795A2 (lt)
CA (1) CA2898496A1 (lt)
CY (1) CY1120481T1 (lt)
DK (1) DK2948559T3 (lt)
EA (1) EA037308B1 (lt)
ES (1) ES2671434T3 (lt)
HR (1) HRP20181055T1 (lt)
HU (1) HUE039465T2 (lt)
IL (1) IL239927B (lt)
LT (1) LT2948559T (lt)
MX (1) MX365987B (lt)
NZ (1) NZ709913A (lt)
PH (1) PH12015501627B1 (lt)
PL (1) PL2948559T3 (lt)
PT (1) PT2948559T (lt)
RS (1) RS57422B1 (lt)
SG (1) SG11201505508TA (lt)
SI (1) SI2948559T1 (lt)
SM (1) SMT201800357T1 (lt)
TR (1) TR201809377T4 (lt)
UA (1) UA117824C2 (lt)
WO (1) WO2014116937A1 (lt)
ZA (1) ZA201506131B (lt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10246496B2 (en) * 2014-08-15 2019-04-02 La Trobe University Potassium channel blockers and use thereof in the treatment of autoimmune diseases
JP6689872B2 (ja) 2015-03-05 2020-04-28 プレジデント アンド フェローズ オブ ハーバード カレッジ 柔軟適応ロボットグラスパ
AU2017260232B2 (en) 2016-05-02 2024-07-18 Abcellera Boston, Inc. Anti-Kv1.3 antibodies, and methods of production and use thereof
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
TW201808987A (zh) * 2016-06-08 2018-03-16 健生生物科技公司 Ｇｍ－ｃｓｆ變體及使用方法
CN106589092A (zh) * 2016-12-22 2017-04-26 中国科学技术大学先进技术研究院 一种蝎毒素多肽及制备拥有类似天然生理功能的蝎毒素多肽的方法
CN106957357B (zh) * 2017-04-01 2021-02-19 合肥科生景肽生物科技有限公司 一种蝎毒素多肽及其合成方法
MY205905A (en) 2018-10-22 2024-11-20 Janssen Pharmaceutica Nv Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof
EP4031162A1 (en) 2019-09-20 2022-07-27 Zealand Pharma A/S Kv1.3 blockers
IL305219A (en) 2021-03-23 2023-10-01 Zealand Pharma As Line suppressors 1.3 which have been changed
EP4604984A1 (en) 2022-10-18 2025-08-27 Zealand Pharma A/S Inhibitors
WO2026003546A1 (en) 2024-06-27 2026-01-02 Vrg Miniprotein Zrt Potassium ion kv1.3 channel inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2243007T3 (es) 1997-09-16 2005-11-16 Egea Biosciences Llc Sintesis quimica completa y sintesis de genes de genomas.
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
GB0414272D0 (en) * 2004-06-25 2004-07-28 Cellpep Sa OsK1 derivatives
EP2474316B1 (en) 2004-10-07 2016-04-06 The Regents of The University of California Analogs of shk toxin and their uses in selective inhibition of kv1.3 potassium channels
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
PE20081140A1 (es) 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
MX2009012609A (es) * 2007-05-22 2009-12-07 Amgen Inc Composiciones y metodos para producir proteinas de fusion bioactivas.
EP2229473A4 (en) * 2007-12-07 2011-02-02 Steven A Goldstein IDENTIFICATION OF TOXIN LIGANDS
EP2328595A1 (en) * 2008-08-13 2011-06-08 The University Of British Columbia Methods for stimulating chondrogenesis utilizing a potassium channel inhibitor
JP2012521197A (ja) * 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド 担体免疫グロブリンおよびその使用
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules

Also Published As

Publication number Publication date
PT2948559T (pt) 2018-07-24
IL239927B (en) 2020-10-29
JP2016505639A (ja) 2016-02-25
SMT201800357T1 (it) 2018-09-13
PH12015501627A1 (en) 2015-09-21
EP2948559A1 (en) 2015-12-02
BR112015017795A2 (pt) 2017-11-21
ZA201506131B (en) 2017-06-28
MX365987B (es) 2019-06-20
PL2948559T3 (pl) 2018-09-28
HRP20181055T1 (hr) 2018-09-07
NZ709913A (en) 2019-05-31
EP2948559A4 (en) 2016-10-19
EP2948559B1 (en) 2018-05-02
WO2014116937A1 (en) 2014-07-31
US20140255401A1 (en) 2014-09-11
US10179808B2 (en) 2019-01-15
EA201591380A1 (ru) 2015-12-30
JP6469590B2 (ja) 2019-02-13
KR102268830B1 (ko) 2021-06-24
RS57422B1 (sr) 2018-09-28
CN104937105A (zh) 2015-09-23
MX2015009632A (es) 2015-11-30
ES2671434T3 (es) 2018-06-06
EA037308B1 (ru) 2021-03-10
PH12015501627B1 (en) 2020-12-11
SI2948559T1 (en) 2018-08-31
US20190062383A1 (en) 2019-02-28
HUE039465T2 (hu) 2019-01-28
KR20150108912A (ko) 2015-09-30
DK2948559T3 (en) 2018-05-28
TR201809377T4 (tr) 2018-07-23
IL239927A0 (en) 2015-08-31
CA2898496A1 (en) 2014-07-31
CY1120481T1 (el) 2019-07-10
UA117824C2 (uk) 2018-10-10
SG11201505508TA (en) 2015-08-28
AU2014209227A1 (en) 2015-07-30
AU2014209227B2 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
NO2023013I1 (no) Combination of foslevodopa and foscarbidopa, each in all forms protected by the basic patent
IL251674B (en) Novel cho integration sites and uses thereof
LT2970303T (lt) Pakeistieji ksantinai ir jų panaudojimo metodai
LT3116909T (lt) Antikūno molekulės prieš lag-3 ir jų panaudojimas
PL3587417T3 (pl) Benzamidy podstawione 1,3-tiazol-2-ilem
LT2968443T (lt) Hepcidino analogai ir jų naudojimas
LT3003039T (lt) Metil/fluor-piridinil-metoksi grupės pakeistieji piridinono-piridinilo junginiai ir fluor-pirimidinil-metoksi grupės pakeistieji piridinono-piridinilo junginiai
LT2989088T (lt) Dolastatino 10 ir auristatinų dariniai
HRP20260361T1 (hr) Supstituirani 4-fenilpiperidini, njihova priprava i uporaba
DK3143037T3 (da) Alpha4beta7-integrin-thioether-peptidantagonister
LT3319612T (lt) Oksisteroliai ir jų naudojimo būdai
DK2961835T3 (da) Ny bakteriophag og antibakteriel sammensætning omfattende samme
IL245471A0 (en) Fluorinated av integrin antagonists
ZA201506131B (en) Kv1.3 antagonists and methods of use
LT3030519T (lt) Tricikliniai benzoksaborolo junginiai ir jų naudojimas
LT3169307T (lt) Vandeninė kompozicija, apimanti paracetamolį ir ibuprofeną
PL3331063T3 (pl) Akumulator i zespół akumulatorowy
LT3337506T (lt) Deriniai ir jų panaudojimas
DK3658413T3 (da) Godssikringsenhed
LT3140318T (lt) Kv1.3 kalio kanalų antagonistai
LT3247711T (lt) Naujos scy-078 druskos ir polimorfai
LT3060660T (lt) Rekombinantiniai glikoproteinai ir jų naudojimas
LT3066091T (lt) Nmda antagonistų pirmtakai
EP3298014A4 (en) S1pr2 antagonists and uses therefor
FI20145740A7 (fi) Sovitelma puomistossa